Sanofi-Aventis buys insulin plant in Russia
This article was originally published in Scrip
Executive Summary
Sanofi-Aventis Europe has bought a 74% stake in Bioton-Vostok, a Russian manufacturer of insulins. If the deal is approved by antimonopoly authorities, the plant will become Sanofi-Aventis's first production facility in Russia.